பில் ல்ுஇள்லிேற் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பில் ல்ுஇள்லிேற். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பில் ல்ுஇள்லிேற் Today - Breaking & Trending Today

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
The poster
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658
, will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020. ....

United States , Christine Schuberth Wagner , Katja Arnold , Wachstumsfonds Bayern , Phil Lhuilier , Shaun Brown , Kostenloser Wertpapierhandel , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , European Union , European Fund For Strategic Investments , Novartis Venture Fund , Distribution Services , Catalym Gmbh , Present Initial Data , First In Human Trial , American Society , Clinical Oncology , Developmental Therapeutics , Eugen Leo , Chief Medical Officer , Chief Scientific Officer , Phill Huillier , Chief Executive Officer ,

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that . ....

United States , Christine Schuberth Wagner , Katja Arnold , Wachstumsfonds Bayern , Phil Lhuilier , Shaun Brown , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , European Union , European Fund For Strategic Investments , Novartis Venture Fund , American Society , Clinical Oncology , Developmental Therapeutics , Eugen Leo , Chief Medical Officer , Chief Scientific Officer , Phill Huillier , Chief Executive Officer , Meeting Proceedings , Growth Differentiation , Ted Effector , Growth And Differentiation Factor , Biogeneration Ventures ,

CatalYm Appoints Industry Leader Dr. Phil L'Huillier as Chief Executive Officer

Share:
MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L Huillier brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnerships. His experience reflects an international career in business, science, and academia.
Dr. Phil L Huillier joins CatalYm from a position as Head of the European Innovation Hub & Business Development at MSD (known as Merck & Co. in North America). In this position he was an active member of MSD global Business Development and Licensing Leadership as well leading a team of scientific and business development professionals that were focused on the identification, evaluation and develo ....

New Zealand , United States , Katja Arnold , Wachstumsfonds Bayern , Artios Pharma , Shaun Brown , John Haurum , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , Board Member Of Cancer Research Technology , European Fund For Strategic Investments , Merck Co , European Union , University Of Auckland , Novartis Venture Fund , Business Development , Phill Huillier , Chief Executive Officer , European Innovation Hub , North America , Licensing Leadership , Executive Director , Board Member , Cancer Research Technology ,

CatalYm Appoints Industry Leader Dr. Phil L'Huillier as

MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the. ....

New Zealand , United States , Katja Arnold , Wachstumsfonds Bayern , Artios Pharma , Shaun Brown , John Haurum , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , Board Member Of Cancer Research Technology , European Fund For Strategic Investments , Merck Co , European Union , University Of Auckland , Novartis Venture Fund , Business Development , Phill Huillier , Chief Executive Officer , European Innovation Hub , North America , Licensing Leadership , Executive Director , Board Member , Cancer Research Technology ,

CatalYm Appoints Industry Leader Dr. Phil L'Huillier as Chief Executive Officer

CatalYm Appoints Industry Leader Dr. Phil L'Huillier as Chief Executive Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New Zealand , United States , Catalym Gmb , Wachstumsfonds Bayern , Artios Pharma , Phil Lhuillier , Catalym Gmbham Klopferspitz , Joerg Wischhusen , John Haurum , European Union , Board Member Of Cancer Research Technology , European Fund For Strategic Investments , Merck Co , Novartis Venture Fund , University Of Auckland , Business Development , Phill Huillier , Chief Executive Officer , European Innovation Hub , North America , Licensing Leadership , Executive Director , Board Member , Cancer Research Technology , Non Executive Director , Achilles Therapeutic Artios Pharma ,